menu

Personalizing Prophylaxis for Hemophilia A and B: A New Era in Treatment and Management

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Personalizing Prophylaxis for Hemophilia A and B:
A New Era in Treatment and Management

close
0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Hemophilia A and hemophilia B are congenital X-linked bleeding disorders caused by deficiency of coagulation factor VIII (FVIII) and IX (FIX). While the life expectancy of patients with hemophilia has dramatically increased over the past several decades, the hemophilia population still faces unique challenges that require appropriate use of effective strategies. The preferred treatment option for patients with hemophilia is replacement therapy. Prophylaxis with standard recombinant factor requires regular intravenous infusion at least two (FIX) to three (FVIII) times a week. Recombinant FVIII and FIX products with an extended half-life are currently available and newer strategies are on the horizon. With reported mean half-life extensions of 1.5–1.8 times that of standard products for FVIII and 3–5 times that of standard products for FIX, these therapies have the potential to address and individualize the needs of patients.

    Click here to access patient information on hemophilia from the CDC.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity. All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty has reported real or apparent conflicts of interest that have been resolved:

    Steven W. Pipe, MD has disclosed the following relevant financial relationships:
    Consultant: Apcintex, Bayer, Biomarin Pharmaceuticals, Catalyst Biosciences, CSL Behring, Hema Pharmaceuticals, Freeline Therapeutics, NovoNordisk, Pfizer, Roche/Genentech, Sangamo Therapeutics, Sanofi US, Spark Therapeutics, Takeda, uniQure
    Research Support: Siemens

    John J. Russell, MD (host) has disclosed the following relevant financial relationships:
    Advisory Board Member: Bayer and GlaxoSmithKline
    Speaker and Advisory Board Member: Sanofi US

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:

    Susan Tyler, PhD, CMP, CHCP, CME Director, has nothing to disclose.
    Bruce Gebhardt, MD, CME Reviewer, has nothing to disclose.
    Heather Muskopf, Program Manager, has nothing to disclose.
    Otto Ratz, MD, has nothing to disclose.
    Christina Culbert, MSc, has nothing to disclose.

  • Target Audience

    This continuing medical education (CME) activity is intended for physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with hemophilia A and hemophilia B.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the barriers and challenges associated with the management of hemophilia A and hemophilia B;
    • Evaluate the clinical data of extended half-life factors and newer strategies to traditional replacement therapies and their potential to result in improved outcomes;
    • Develop a strategy for how to incorporate EHL and newer strategies as part of an individualized approach to prophylactic management of hemophilia.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Provider
    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This program is supported by an educational grant from Sanofi US and Novo Nordisk, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Hemophilia A and hemophilia B are congenital X-linked bleeding disorders caused by deficiency of coagulation factor VIII (FVIII) and IX (FIX). While the life expectancy of patients with hemophilia has dramatically increased over the past several decades, the hemophilia population still faces unique challenges that require appropriate use of effective strategies. The preferred treatment option for patients with hemophilia is replacement therapy. Prophylaxis with standard recombinant factor requires regular intravenous infusion at least two (FIX) to three (FVIII) times a week. Recombinant FVIII and FIX products with an extended half-life are currently available and newer strategies are on the horizon. With reported mean half-life extensions of 1.5–1.8 times that of standard products for FVIII and 3–5 times that of standard products for FIX, these therapies have the potential to address and individualize the needs of patients.

    Click here to access patient information on hemophilia from the CDC.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity. All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty has reported real or apparent conflicts of interest that have been resolved:

    Steven W. Pipe, MD has disclosed the following relevant financial relationships:
    Consultant: Apcintex, Bayer, Biomarin Pharmaceuticals, Catalyst Biosciences, CSL Behring, Hema Pharmaceuticals, Freeline Therapeutics, NovoNordisk, Pfizer, Roche/Genentech, Sangamo Therapeutics, Sanofi US, Spark Therapeutics, Takeda, uniQure
    Research Support: Siemens

    John J. Russell, MD (host) has disclosed the following relevant financial relationships:
    Advisory Board Member: Bayer and GlaxoSmithKline
    Speaker and Advisory Board Member: Sanofi US

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:

    Susan Tyler, PhD, CMP, CHCP, CME Director, has nothing to disclose.
    Bruce Gebhardt, MD, CME Reviewer, has nothing to disclose.
    Heather Muskopf, Program Manager, has nothing to disclose.
    Otto Ratz, MD, has nothing to disclose.
    Christina Culbert, MSc, has nothing to disclose.

  • Target Audience

    This continuing medical education (CME) activity is intended for physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with hemophilia A and hemophilia B.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the barriers and challenges associated with the management of hemophilia A and hemophilia B;
    • Evaluate the clinical data of extended half-life factors and newer strategies to traditional replacement therapies and their potential to result in improved outcomes;
    • Develop a strategy for how to incorporate EHL and newer strategies as part of an individualized approach to prophylactic management of hemophilia.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Provider
    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This program is supported by an educational grant from Sanofi US and Novo Nordisk, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule28 Oct 2021
Webpack App